Press Room - Sanofi US News

Media Room Menu

Feb 11, 2009

New England Journal of Medicine Publishes Results from the Landmark ATHENA Trial with Multaq® (dronedarone) in Atrial Fibrillation

Multaq(R) (dronedarone) significantly reduced the risk of cardiovascular hospitalization or death by 24 percent in patients with atrial fibrillation
Feb 5, 2009

Inspirational Teams of Athletes with Diabetes Build Momentum in 2009 with Sponsorship from Long-Acting Insulin Lantus® and Rapid-Acting Insulin Apidra®

Team Type 1 Expands Its Roster, Fielding Five Teams to Spread Personal Messages of Successful Diabetes Management to People Living with Type 1 and Type 2 Diabetes
Nov 11, 2008

Dronedarone (Multaq®) Reduced the Incidence and Duration of Hospitalization in Patients with Atrial Fibrillation

New post-hoc analysis from Athena Study showed that Multaq® on top of standard therapy significantly decreased the total number of hospital days by 28% in patients with atrial fibrillation or flutter
Oct 29, 2008

FDA Approves Rapid-Acting Insulin Apidra® for Treatment of Children with Diabetes
Oct 23, 2008

Sanofi-aventis is Complying With the EMEA’s Recommendation to Temporarily Suspend the Marketing Authorization of Acomplia® in Obese and Overweight Patients

Sanofi-aventis will comply with the European Authorities request to temporarily suspend the marketing authorisation of Acomplia® in obese and overweight patients and will make every effort to actively support patients and Health Care Professionals.

Show per page